Loading...

뉴스 목록

Roche has released new clinical data showing that monoclonal antibodies sustainably slow the progression of Parkinson's disease

2024-10-19


Recently, Roche (Roche) researchers published in the international top medical journal Nature Medicine entitled: Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open-label extension of the PASADENA  trial research paper.

The study revealed data from the open-label extension study of Prasinezumab, a monoclonal antibody targeting alpha-synuclein (alpha-SYN) in the PASADENA clinical trial, showing that Prasinezumab has a long-term sustained effect on motor progression in patients with Parkinson's disease.